Sotorasib (AMG 510) is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. In December 2019, it was approved to begin Phase 2 clinical trials.

Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocarcinoma patients and 5% of colorectal cancer patients, and sotorasib is the first drug candidate to target this mutation, there have been high expectations for the drug.The Food and Drug Administration has granted a fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma with the G12C KRAS mutation.

Function
AMG-510 is a KRAS G12C inhibitor. Because it interrupts protein signaling, it causes KRAS G12C tumor regression.

Hot Products

Packing

FAQ

Q1: Can i get some samples?
 A: Yes, we can supply the free sample, but the shipping cost be paid by our customers.

Q2: How to start orders or make payments? 
A: Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T,Western Union or Paypal.

Q3: How to confirm the Product Quality before placing orders? 
A:You can get free samples for some products,you only need to pay the shipping cost or arrange a courier to us and take the samples. You can send us your product specifications and requests,we will manufacture the products according to your requests.

Q4:What's your MOQ?
 A:Our MOQ is 1kg. But usually we accept less quantity such as 10g on the condition that sample charge is 100% paid.

Q5: How about delivery lead time?
 A:Delivery lead time: About 3-5 days after payment confirmed. (Chinese holiday not included)